COVID-19 in depth.

Overview

COVID-19 is an acute respiratory disease. Caused by SARS-CoV-2 (a betacoronavirus), it spreads through respiratory droplets and airborne aerosols in enclosed spaces. Key symptoms: fever or chills, persistent cough, shortness of breath, and loss of taste or smell. Most infections are mild to moderate; around 1–2% of confirmed cases are fatal, with higher mortality in older adults and immunocompromised individuals.

SARS-CoV-2 is an enveloped, single-stranded positive-sense RNA virus whose spike protein (S protein) binds the ACE2 receptor on human cells. The rapid evolution of the spike protein has produced multiple variants of concern — Alpha, Beta, Delta, and Omicron — each with altered transmissibility and immune evasion profiles. The pandemic accelerated the development of mRNA vaccine technology (Pfizer-BioNTech BNT162b2, Moderna mRNA-1273) and produced the largest vaccine roll-out in human history.

Despite widespread vaccination, SARS-CoV-2 has transitioned to endemic circulation with ongoing seasonal waves. Long COVID — symptoms persisting beyond 12 weeks after infection — affects an estimated 65 million people worldwide and has emerged as a major chronic disease burden reshaping disability statistics and healthcare utilization globally.

History & Origin

The first cluster of pneumonia cases of unknown cause was reported to the WHO on 31 December 2019 from Wuhan. The novel coronavirus was identified on 7 January 2020. SARS-CoV-2 shares ~96.2% genome sequence identity with bat coronavirus RaTG13, suggesting a bat reservoir. The precise origin — zoonotic spillover at the Wuhan seafood market or a laboratory incident — remains under investigation.

The WHO declared a Public Health Emergency of International Concern (PHEIC) on 30 January 2020. Major variant-driven waves: Alpha (UK, late 2020), Delta (India, early 2021), and Omicron (South Africa, November 2021) — with the most dramatic transmissibility jump (R₀ ~15–20). The WHO declared the end of COVID-19 as a global health emergency on 5 May 2023, though SARS-CoV-2 continues to circulate in Omicron subvariants (JN.1, KP.2) through 2025.

Transmission

• Respiratory aerosols and droplets: Primary route. Infected persons release virus-laden particles when breathing, speaking, singing, coughing, or sneezing. Aerosols (<5 µm) can remain airborne for hours in poorly ventilated indoor spaces — "airborne transmission" confirmed by WHO.
• Presymptomatic transmission: ~40–59% of transmission occurs before symptom onset, making isolation of symptomatic cases alone insufficient.
• Close contact: Within 1–2 metres of an infectious person significantly increases risk.
• Fomites: Contact with contaminated surfaces followed by touching the face is a minor route.
• Omicron factors: Shorter incubation (2–3 days), higher upper respiratory replication — masks and ventilation remain critical.

Symptom Timeline

Incubation: typically 2–14 days (median 5–7 days for original strain; 2–3 days for Omicron).

Diagnosis

• Rapid antigen tests (RAT/LFT): Detect SARS-CoV-2 nucleocapsid protein. Results in 15–30 minutes. Sensitivity 60–80% vs PCR, higher during peak viremia. Used for home testing.
• RT-PCR: Gold standard. Sensitivity >95%, specificity ~99%. Results in 4–24 hours. Cycle threshold (Ct) value indicates viral load. Used for confirmation and surveillance.
• CT scanning: Bilateral peripheral ground-glass opacities characteristic. Useful in severe pneumonia; not recommended for routine diagnosis.
• Blood tests: Elevated CRP, ferritin, D-dimer, and IL-6 in severe disease. Lymphopaenia characteristic. Elevated troponin/LDH indicates organ stress.

Treatment

Mild Disease (Home)

• Paracetamol for fever and pain; adequate rest and hydration; self-isolation
• Nirmatrelvir/ritonavir (Paxlovid): Approved for mild-moderate high-risk patients within 5 days of symptom onset; 89% reduction in hospitalisation in trials. Requires prescription; check drug interactions.
• Molnupiravir: Alternative oral antiviral for high-risk patients unable to take Paxlovid.

Hospitalised (Moderate-Severe)

• Dexamethasone 6 mg/day × 10 days: WHO-recommended for patients requiring oxygen; 36% reduction in 28-day mortality (RECOVERY trial)
• Remdesivir: IV antiviral; reduces time to recovery in hospitalised patients
• Baricitinib, Tocilizumab: JAK inhibitor and IL-6 antagonist; reduce mortality in severe disease
• Prone positioning improves oxygenation in ARDS; mechanical ventilation for refractory hypoxaemia
• Anticoagulation: prophylactic heparin for all hospitalised patients

Vaccines

• Pfizer-BioNTech (BNT162b2 / Comirnaty): First authorised mRNA vaccine (December 2020). 95% efficacy against original strain. Updated annually to target current variants. Used in 160+ countries.
• Moderna (mRNA-1273 / Spikevax): 94.1% efficacy against original strain. Updated bivalent versions target Omicron subvariants.
• Novavax (NVX-CoV2373): Protein subunit vaccine; ~90% efficacy; preferred by those hesitant about mRNA technology.
• AstraZeneca, Johnson & Johnson: Viral vector vaccines (withdrawn in many countries due to rare VITT — vaccine-induced thrombocytopenia and thrombosis).
• Coronavac, Covaxin, Sinopharm: Inactivated virus vaccines widely used in Asia, South America, and Africa.

COVID-19 vaccines prevented an estimated 19.8 million deaths in the first year of roll-out alone (Watson et al., Lancet 2022).

Global Impact

COVID-19 caused the greatest global health crisis since the 1918 influenza pandemic. Over 703 million confirmed cases, 7+ million confirmed deaths (excess mortality estimates: 15–20 million), and economic losses exceeding $13.8 trillion in lost output (IMF).

The pandemic exposed and exacerbated global health inequities. Low-income countries faced late vaccine access, health system collapse, and disproportionate excess mortality. Healthcare systems worldwide were overwhelmed, leading to deferred care for non-COVID conditions and millions of indirect excess deaths.

Long COVID is reshaping disability statistics and workforce participation globally. With no proven treatment, millions of people with Long COVID face years of debilitating symptoms including fatigue, brain fog, and cardiovascular complications.

SARS-CoV-2 Variants: Key Evolution

Virology: SARS-CoV-2 in Detail

SARS-CoV-2 is a betacoronavirus with a ~30 kb positive-sense RNA genome — the largest RNA genome of any known virus. Key structural proteins include the spike (S) protein (mediates ACE2 receptor binding and membrane fusion), nucleocapsid (N), envelope (E), and membrane (M) proteins. The spike protein has a receptor-binding domain (RBD) that binds human ACE2 with ~10–20× higher affinity than SARS-CoV-1, explaining its pandemic success. The furin cleavage site in the spike (PRRA insertion) facilitates efficient activation of membrane fusion — a feature absent in most other coronaviruses and a key virulence factor.

SARS-CoV-2 replicates primarily in the upper respiratory tract (nasal epithelium, nasopharynx), explaining its high transmissibility through respiratory droplets and aerosols. However, it can infect ACE2-expressing cells throughout the body — lower respiratory tract, intestines, kidneys, heart, brain — explaining multi-system disease in severe COVID-19 and the diverse manifestations of Long COVID.

Pathophysiology: How COVID-19 Causes Severe Disease

• Phase 1 — Viral replication: Upper respiratory tract replication; most mild disease is restricted to this phase; innate immune response controls infection in most people
• Phase 2 — Pulmonary phase: In some patients, virus spreads to lower respiratory tract; interstitial pneumonia, diffuse alveolar damage; characteristic CT finding: bilateral ground-glass opacities (GGO)
• Phase 3 — Hyperinflammatory/cytokine storm: Dysregulated immune response with IL-6, TNF-α, IL-1β surge; endothelial damage; microthrombi in pulmonary vasculature; ARDS; multi-organ failure
• Coagulopathy: COVID-19 causes hypercoagulable state — deep vein thrombosis, pulmonary embolism, stroke risk elevated; anticoagulation recommended in hospitalized patients
• Cardiovascular: Myocarditis, pericarditis, arrhythmias documented; myocarditis risk higher with infection than with vaccination

Long COVID: Post-Acute Sequelae

Long COVID (post-acute sequelae of SARS-CoV-2 infection, PASC) refers to symptoms persisting >4 weeks after acute illness. WHO estimates 10–20% of COVID-19 cases experience some Long COVID symptoms; approximately 1–3% develop disabling long-term illness. Major Long COVID phenotypes include:

• Post-exertional malaise (PEM): Disproportionate worsening of symptoms after physical or cognitive effort — the cardinal feature distinguishing Long COVID from normal recovery
• Dysautonomia/POTS: Postural orthostatic tachycardia syndrome — heart rate increases >30 bpm on standing; dizziness, palpitations, fatigue
• Cognitive dysfunction ("brain fog"): Memory impairment, concentration difficulties, executive function impairment — documented on neuropsychological testing
• Cardiopulmonary: Breathlessness, palpitations, chest pain on exertion
• Fatigue: Profound fatigue distinct from depression — the most common Long COVID symptom
• Sensory: Persistent anosmia/parosmia (distorted smell), taste changes
• Proposed mechanisms: Viral persistence in tissues (gut reservoir); microbiome disruption; autoimmunity (molecular mimicry); reactivation of latent viruses (EBV); vascular endothelial dysfunction; microclots

COVID-19 vs Influenza: Key Differences

COVID-19 Treatments (2024 Status)

• Nirmatrelvir/ritonavir (Paxlovid, Pfizer): Oral protease inhibitor; 89% reduction in severe disease/death when started within 5 days; first-line for high-risk non-hospitalized patients. Significant drug interactions via CYP3A4 (ritonavir boosting). Available for age 12+ in most countries.
• Remdesivir (Veklury, Gilead): RNA polymerase inhibitor; IV formulation; WHO recommends for oxygen-requiring hospitalized patients. Reduces ICU admissions.
• Molnupiravir (Lagevrio, MSD/Ridgeback): Oral RNA mutagenic agent; ~30% reduction in hospitalization; less effective than Paxlovid; alternative when Paxlovid not tolerated.
• Dexamethasone: Corticosteroid; RECOVERY trial (2020) showed 35% mortality reduction in mechanically ventilated patients; standard of care for severe COVID.
• Tocilizumab/sarilumab: IL-6 receptor antagonists; reduce mortality in hyperinflammatory severe COVID; used in ICU.
• Baricitinib: JAK inhibitor; reduces mortality in severe COVID; WHO recommends alongside dexamethasone.
• COVID-19 vaccines: Remain highly effective against severe disease, hospitalization, death even against Omicron subvariants. Annual updated boosters targeting dominant circulating strains recommended for high-risk groups.

Country-Specific Information

Frequently Asked Questions

Sources & Citations

COVID-19 in Children & Pediatric MIS-C

Children generally have milder COVID-19 than adults. Most pediatric cases are asymptomatic or mild. However, children can develop serious complications:

• MIS-C (Multisystem Inflammatory Syndrome in Children): A serious condition occurring 2–6 weeks after SARS-CoV-2 infection; affects multiple organ systems. Features: persistent fever, rash, abdominal pain, vomiting, conjunctivitis, cardiac involvement (coronary artery dilation, myocarditis), elevated inflammatory markers (CRP, ferritin, D-dimer). Rare but well-established — ~6 per 100,000 COVID-19 cases in children. Treatment: IV immunoglobulin (IVIg) and corticosteroids; aspirin for coronary involvement. Most children recover fully; rare deaths reported.
• Severe pediatric COVID: Higher risk in children with obesity, diabetes, immunocompromise, or complex medical needs; younger infants (<1 year) have higher hospitalization rates than school-age children
• Long COVID in children: Fatigue, cognitive symptoms, and headaches documented in children; lower prevalence than adults but significant in aggregate given large numbers infected
• COVID vaccines for children: Available for children 6 months+ in many countries; recommended for high-risk children; reduces MIS-C risk

COVID-19 Mental Health Impact

The COVID-19 pandemic caused unprecedented global mental health burden, both from the disease itself and from pandemic-related social/economic disruption:

• WHO estimates global prevalence of anxiety and depression increased by 25% in the first year of the pandemic
• Healthcare workers experienced particularly high rates of burnout, PTSD, depression, and anxiety following the COVID-19 pandemic — with many leaving the profession
• Social isolation (especially elderly in lockdowns), grief from losses, economic stress, and "pandemic fatigue" contributed to mental health deterioration globally
• Long COVID neuropsychiatric symptoms — brain fog, depression, anxiety — affect an estimated 10–15% of COVID-19 cases and can persist for years
• Adolescents and young people: school closures, social isolation, and disruption of developmental milestones caused lasting mental health impacts; increases in depression, anxiety, self-harm, and eating disorders documented worldwide

COVID-19 Global Impact & Economic Consequences

COVID-19's global impact was unprecedented in scope:

• Deaths: WHO excess mortality estimates suggest 14.9 million excess deaths globally in 2020–2021 alone; official COVID-19 deaths reported at 7+ million, but true excess mortality far higher due to indirect deaths (delayed care for other conditions) and undercounting in low-resource settings
• Economic: Global GDP fell 3.5% in 2020 — worst recession since WWII. Cumulative global GDP loss estimated at $13.8 trillion (IMF). Developing nations disproportionately affected due to reliance on tourism and informal economy sectors.
• Healthcare disruption: Routine vaccination campaigns disrupted globally, potentially contributing to disease resurgences (measles, polio). Cancer screening and treatment delayed, leading to later-stage diagnoses. Mental health services overwhelmed.
• Vaccine inequity: By end of 2021, 80% of vaccines administered in high-income countries; Africa received <3% of global vaccine doses. The COVAX facility aimed to address this but was underfunded and outcompeted by bilateral deals.
• Scientific acceleration: mRNA vaccine technology validated at scale; largest ever global clinical trial network mobilized; pandemic led to accelerated development of antivirals (Paxlovid, remdesivir, molnupiravir) and treatments (dexamethasone).

Related Diseases

Key Terms: COVID-19

• SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2 — the causative betacoronavirus of COVID-19; member of the Sarbecovirus subgenus
• Spike protein: The surface protein of SARS-CoV-2 that mediates binding to the ACE2 receptor and membrane fusion; the primary target of COVID-19 vaccines and key determinant of immune escape in variants
• ACE2: Angiotensin-converting enzyme 2 — the primary cell surface receptor used by SARS-CoV-2 for entry into host cells; expressed in lung, intestine, heart, brain, and other tissues
• Omicron: The B.1.1.529 SARS-CoV-2 variant that emerged in November 2021; carries 30+ spike mutations enabling significant immune escape; currently dominant globally with many sublineages (JN.1, KP.2, etc.)
• Long COVID (PASC): Post-acute sequelae of SARS-CoV-2 infection — symptoms persisting >4 weeks after acute infection; estimated 10-20% of COVID cases; manifests as fatigue, brain fog, POTS, and many other symptoms
• mRNA vaccine: Vaccine that delivers mRNA encoding the SARS-CoV-2 spike protein, prompting cells to produce the antigen and stimulate immunity; platform validated at scale by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax)
• Paxlovid: Oral COVID-19 antiviral (nirmatrelvir + ritonavir); first-line treatment for high-risk non-hospitalized COVID patients within 5 days of symptom onset; 89% reduction in severe disease
• ARDS: Acute Respiratory Distress Syndrome — severe respiratory failure caused by widespread lung inflammation and fluid accumulation; common in severe COVID-19; requires mechanical ventilation
• RECOVERY trial: The UK Randomised Evaluation of COVID-19 Therapy — the largest COVID treatment trial, enrolling 40,000+ patients; established dexamethasone, tocilizumab, baricitinib as effective treatments for severe COVID
• MIS-C: Multisystem Inflammatory Syndrome in Children — a serious post-COVID complication affecting multiple organ systems, occurring 2-6 weeks after SARS-CoV-2 infection in children

More COVID-19 Questions

Epidemiology at a Glance: COVID-19

Official COVID-19 death counts globally are significant undercounts. WHO excess mortality methodology provides more reliable estimates of true pandemic death toll.

COVID-19 Protection — 2025 Guidance Summary

• Stay up to date on COVID-19 vaccines: Annual updated booster targeting current circulating strains recommended for: elderly (60+), immunocompromised, pregnant women, high-risk medical conditions, and healthcare workers. Check local guidance for your country.
• If you test positive and are high-risk: Contact your doctor immediately within 5 days of symptom onset about Paxlovid (nirmatrelvir/ritonavir) — 89% reduction in severe disease. Note drug interactions.
• Indoor ventilation: SARS-CoV-2 spreads primarily via aerosols. Improve indoor air quality with CO₂ monitoring, HEPA filtration, and fresh air ventilation — most cost-effective non-pharmaceutical intervention.
• Masks when sick: If you test positive or have respiratory symptoms, wear a well-fitting mask (N95/FFP2 preferred) around others until symptoms resolve.
• Test before gatherings: Rapid antigen tests before visiting elderly, immunocompromised, or high-risk individuals reduce risk of transmission.
• Long COVID awareness: If you develop persistent fatigue, brain fog, or shortness of breath >4 weeks after COVID-19, seek medical evaluation. Pacing and specialist referral may be needed.
• Infection control in healthcare settings: Continue to implement source control (masks for symptomatic patients), hand hygiene, and airborne precautions for COVID patients requiring aerosol-generating procedures.

COVID-19: End of Pandemic Questions